Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12946163 | 0.80 | HTR1A (0.58) | HTR1AHTR7KDM4EALDH1A1PRMT5 | |
| SCHEMBL8273954 | 0.79 | HTR7 (0.55) | HTR1AHTR7KDM4EALDH1A1PRMT5 | |
| SCHEMBL6796174 | 0.79 | OPRL1 (0.58) | HTR1AHTR7PRMT5WDR77 | |
| SCHEMBL6797005 | 0.78 | DRD2 (0.59) | HTR1AHTR7KDM4EALDH1A1PRMT5 | |
| SCHEMBL6798006 | 0.74 | HTR1A (0.75) | HTR1AHTR7KDM4EALDH1A1 | |
| SCHEMBL6397901 | 0.74 | MCHR2 (0.53) | CCR2MCHR2 | |
| SCHEMBL12913435 | 0.74 | ALDH1A1 (0.56) | HTR1AHTR7KDM4EALDH1A1PRMT5 | |
| SCHEMBL6802419 | 0.72 | HTR7 (0.57) | HTR1AHTR7KDM4EALDH1A1 | |
| SCHEMBL14445171 | 0.72 | CCR2 (1.00) | CCR2 | |
| SCHEMBL7382052 | 0.72 | MCHR2 (0.58) | CCR2MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | CCR2 4073/4885HTR1A 848/4885HTR7 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.